Last reviewed · How we verify

Intramuscular ziprasidone mesylate — Competitive Intelligence Brief

Intramuscular ziprasidone mesylate (Intramuscular ziprasidone mesylate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic. Area: Psychiatry.

phase 3 Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Intramuscular ziprasidone mesylate (Intramuscular ziprasidone mesylate) — Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Ziprasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Intramuscular ziprasidone mesylate TARGET Intramuscular ziprasidone mesylate Pfizer's Upjohn has merged with Mylan to form Viatris Inc. phase 3 Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor
risperidone (Risperdal) risperidone (Risperdal) University of South Florida marketed Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor
sodium valproate with Clozapine sodium valproate with Clozapine Shanghai Mental Health Center marketed Antipsychotic + mood stabilizer combination Dopamine D2 receptor, serotonin 5-HT2A receptor, GABA pathways, histone deacetylase
Olanzapine-Fluoxetine Combination Olanzapine-Fluoxetine Combination All India Institute of Medical Sciences, Bhubaneswar marketed Atypical antipsychotic + SSRI combination Dopamine D2 receptor, serotonin 5-HT2A receptor, serotonin transporter (SERT)
Quetiapine Fumarate Sustained Release Quetiapine Fumarate Sustained Release AstraZeneca marketed Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor
Risperidone and Ramelteon Risperidone and Ramelteon All India Institute of Medical Sciences, Bhubaneswar marketed Atypical antipsychotic + melatonin receptor agonist combination Dopamine D2 receptor, serotonin 5-HT2A receptor, melatonin MT1/MT2 receptors
paliperidone clozapine paliperidone clozapine Universidad Nacional de Rosario marketed Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic class)

  1. Shanghai Mental Health Center · 10 drugs in this class
  2. AstraZeneca · 6 drugs in this class
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. · 5 drugs in this class
  4. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 4 drugs in this class
  5. Eli Lilly and Company · 4 drugs in this class
  6. Otsuka Pharmaceutical Co., Ltd. · 3 drugs in this class
  7. Medical University of Vienna · 2 drugs in this class
  8. Organon and Co · 2 drugs in this class
  9. Chengdu Kanghong Pharmaceutical Group Co., Ltd. · 2 drugs in this class
  10. H. Lundbeck A/S · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intramuscular ziprasidone mesylate — Competitive Intelligence Brief. https://druglandscape.com/ci/intramuscular-ziprasidone-mesylate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: